Cholesterol lowering and endothelial function.

[1]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[2]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[3]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[4]  M. Corretti,et al.  Cholesterol, cholesterol lowering, and endothelial function. , 1998, Progress in cardiovascular diseases.

[5]  K. Kostner,et al.  Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. , 1998, Journal of the American College of Cardiology.

[6]  R. Schmieder,et al.  Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. , 1998, Circulation.

[7]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[8]  G. Plotnick,et al.  The mechanism of improvement in endothelial function by pravastatin: direct effect or through cholesterol lowering , 1998 .

[9]  G. Plotnick,et al.  Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. , 1997, JAMA.

[10]  M. Creager,et al.  When 'normal' cholesterol levels injure the endothelium. , 1997, Circulation.

[11]  K. Schenck-Gustafsson,et al.  Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. , 1997, Circulation.

[12]  A. Baron,et al.  Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. , 1997, Circulation.

[13]  A. Quyyumi,et al.  Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. , 1997, Journal of the American College of Cardiology.

[14]  W. Erl,et al.  HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. , 1997, Journal of the American College of Cardiology.

[15]  D. Harrison,et al.  Cellular and molecular mechanisms of endothelial cell dysfunction. , 1997, The Journal of clinical investigation.

[16]  T. Lüscher,et al.  Biology of the Endothelium , 1997, Clinical cardiology.

[17]  E. Whitney,et al.  Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. , 1997, The American journal of cardiology.

[18]  M. Rubenfire,et al.  Clinical predictors of oxidized low-density lipoprotein in patients with coronary artery disease. , 1997, The American journal of cardiology.

[19]  R. Schwartz,et al.  Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. , 1997, Circulation.

[20]  B. Hornig,et al.  Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. , 1997, Circulation.

[21]  P. Marraccini,et al.  Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. , 1997, Circulation.

[22]  J. Keaney,et al.  Antioxidants and atherosclerotic heart disease. , 1997, The New England journal of medicine.

[23]  T. Saldeen,et al.  Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. , 1997, Journal of the American College of Cardiology.

[24]  D. Celermajer,et al.  Endothelial dysfunction: does it matter? Is it reversible? , 1997, Journal of the American College of Cardiology.

[25]  J. Jukema,et al.  Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS) , 1997, Circulation.

[26]  T. Lehtimäki,et al.  In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. , 1997, Journal of the American College of Cardiology.

[27]  R. Vogel.  Coronary risk factors, endothelial function, and atherosclerosis: A review , 1997, Clinical cardiology.

[28]  G. Assmann,et al.  Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. , 1997, Circulation.

[29]  D. Green,et al.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.

[30]  D. Celermajer,et al.  Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. , 1997, Journal of the American College of Cardiology.

[31]  G. Plotnick,et al.  Effect of a single high-fat meal on endothelial function in healthy subjects. , 1997, The American journal of cardiology.

[32]  P. Ganz,et al.  Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. , 1997, Circulation.

[33]  T. Imaizumi,et al.  Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. , 1997, Circulation.

[34]  C. Rock,et al.  Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary artery disease. , 1996, Journal of the American College of Cardiology.

[35]  P. Vanhoutte,et al.  Endothelium-derived hyperpolarizing factor. , 1996, Clinical and experimental pharmacology & physiology.

[36]  M. Petch,et al.  Aging-associated endothelial dysfunction in humans is reversed by L-arginine. , 1996, Journal of the American College of Cardiology.

[37]  H. Superko,et al.  Beyond LDL cholesterol reduction. , 1996, Circulation.

[38]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[39]  H. Crijns,et al.  Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. , 1996, Circulation.

[40]  A. Yeung,et al.  Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. , 1996, Circulation.

[41]  J. Mehta,et al.  Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. , 1996, Circulation.

[42]  W. Erl,et al.  Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. , 1996, Circulation.

[43]  C. Ballantyne,et al.  Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia , 1996 .

[44]  R. Virmani,et al.  Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. , 1996, Circulation.

[45]  F. Kelly,et al.  Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) , 1996, The Lancet.

[46]  G. Levine,et al.  Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. , 1996, Circulation.

[47]  P. Ganz,et al.  Atherosclerosis: risk factors and the vascular endothelium. , 1996, American heart journal.

[48]  M. Hori,et al.  Endothelial dysfunction in the early stage of atherosclerosis precedes appearance of intimal lesions assessable with intravascular ultrasound. , 1996, American heart journal.

[49]  G. Plotnick,et al.  Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. , 1996, The American journal of cardiology.

[50]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[51]  S. Yusuf,et al.  The Antioxidant Vitamins and Cardiovascular Disease: A Critical Review of Epidemiologic and Clinical Trial Data , 1995, Annals of Internal Medicine.

[52]  O. Hess,et al.  Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. , 1995, Journal of the American College of Cardiology.

[53]  A. Quyyumi,et al.  Evidence that endothelial dysfunction in patients with hypercholesterolemia is not due to increased extracellular nitric oxide breakdown by superoxide anions. , 1995, The American journal of cardiology.

[54]  G. Mancini,et al.  Effects of vitamin E on endothelial function in men after myocardial infarction. , 1995, The American journal of cardiology.

[55]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[56]  N. Mullani,et al.  Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. , 1995, JAMA.

[57]  C. Wanner,et al.  Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Role of oxygen-derived radicals. , 1995, Circulation.

[58]  T. Rabelink,et al.  Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication , 1995, The Lancet.

[59]  D. Harrison,et al.  Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. , 1995, Circulation.

[60]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[61]  D Kromhout,et al.  Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. , 1995, JAMA.

[62]  A. Heagerty,et al.  In vitro responses of human peripheral small arteries in hypercholesterolemia and effects of therapy. , 1995, Circulation.

[63]  P. Libby.  Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[64]  A. Yeung,et al.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.

[65]  W. Weintraub,et al.  Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.

[66]  G. Levine,et al.  Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. , 1995, The New England journal of medicine.

[67]  A. Quyyumi,et al.  Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. , 1994, Journal of the American College of Cardiology.

[68]  D. Celermajer,et al.  Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. , 1994, Journal of the American College of Cardiology.

[69]  S. Nilsson,et al.  The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). , 1994, The American journal of cardiology.

[70]  M. Sugimachi,et al.  Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.

[71]  V. Maher,et al.  Reversal of coronary heart disease by lipid-lowering therapy. Observations and pathological mechanisms. , 1994, Circulation.

[72]  G. Gibbons,et al.  The emerging concept of vascular remodeling. , 1994, The New England journal of medicine.

[73]  A. Quyyumi,et al.  Investigation of decreased availability of nitric oxide precursor as the mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. , 1994, Journal of the American College of Cardiology.

[74]  M. Yanagisawa.  The endothelin system. A new target for therapeutic intervention. , 1994, Circulation.

[75]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[76]  S. Moncada,et al.  The L-arginine-nitric oxide pathway. , 1993, The New England journal of medicine.

[77]  D. Waters,et al.  Plasma Lipoproteins and Progression of Coronary Artery Disease Evaluated by Angiography and Clinical Events , 1993, Circulation.

[78]  A. Quyyumi,et al.  The Role of Nitric Oxide in Endothelium‐Dependent Vasodilation of Hypercholesterolemic Patients , 1993, Circulation.

[79]  S. Grundy,et al.  Effect of combined supplementation with alpha-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation. , 1993, Circulation.

[80]  O. Hess,et al.  Influence of Serum Cholesterol and Other Coronary Risk Factors on Vasomotion of Angiographically Normal Coronary Arteries , 1993, Circulation.

[81]  C. Lau,et al.  Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients , 1993, The Lancet.

[82]  J. Albers,et al.  Lipid Lowering and Plaque Regression New Insights Into Prevention of Plaque Disruption and Clinical Events in Coronary Disease , 1993, Circulation.

[83]  D. Harrison,et al.  Hypercholesterolemia increases endothelial superoxide anion production. , 1993, The Journal of clinical investigation.

[84]  K. Hirata,et al.  High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. , 1993, Circulation research.

[85]  A. Quyyumi,et al.  Role of Endothelium‐Derived Nitric Oxide in the Abnormal Endothelium‐Dependent Vascular Relaxation of Patients With Essential Hypertension , 1993, Circulation.

[86]  J. Cooke,et al.  Vascular Biology and Medicine in the 1990s: Scope, Concepts, Potentials, and Perspectives , 1993, Circulation.

[87]  J. Cooke,et al.  L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. , 1992, The Journal of clinical investigation.

[88]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[89]  S. Mocanda.  THE L-ARGININE-NITRIC OXIDE PATHWAY , 1992 .

[90]  B. Hoffman,et al.  Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. , 1992, The Journal of clinical investigation.

[91]  H. Drexler,et al.  Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine , 1991, The Lancet.

[92]  E. Mohler,et al.  Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. , 1991, The American journal of cardiology.

[93]  A. Lerman,et al.  Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. , 1991, The New England journal of medicine.

[94]  R. Lawn,et al.  Lipoprotein(a) and atherosclerosis. , 1991, Annals of internal medicine.

[95]  D. Harrison,et al.  Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. , 1990, The Journal of clinical investigation.

[96]  K. Margulies,et al.  Endothelin: a new cardiovascular regulatory peptide. , 1990, Mayo Clinic proceedings.

[97]  M J Davies,et al.  A macro and micro view of coronary vascular insult in ischemic heart disease. , 1990, Circulation.

[98]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[99]  M. Cybulsky,et al.  Endothelial‐Dependent Mechanisms of Leukocyte Adhesion in Inflammation and Atherosclerosis a , 1990, Annals of the New York Academy of Sciences.

[100]  R. Cohen,et al.  Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. , 1990, The Journal of clinical investigation.

[101]  S. Schwartz,et al.  Cell proliferation in human coronary arteries. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[102]  K. Kugiyama,et al.  Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins , 1990, Nature.

[103]  A. Yeung,et al.  Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. , 1990, Circulation.

[104]  J. Breslow,et al.  Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis , 1989, Nature.

[105]  H. Shimokawa,et al.  Hypercholesterolemia causes generalized impairment of endothelium-dependent relaxation to aggregating platelets in porcine arteries. , 1989, Journal of the American College of Cardiology.

[106]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[107]  A. M. Lefer,et al.  Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment. , 1989, The Journal of clinical investigation.

[108]  E. Nabel,et al.  Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. , 1989, Circulation.

[109]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[110]  J. Hainer.  Cholesterol and mortality. , 1987, JAMA.

[111]  D. Levy,et al.  Cholesterol and mortality. 30 years of follow-up from the Framingham study. , 1987, JAMA.

[112]  P. Ganz,et al.  Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. , 1986, The New England journal of medicine.

[113]  R. Ross.  The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.

[114]  V. Fuster,et al.  Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. , 1985, Journal of the American College of Cardiology.

[115]  L V McIntire,et al.  Flow effects on prostacyclin production by cultured human endothelial cells. , 1985, Science.

[116]  M. Gimbrone,et al.  Influence of hemodynamic forces on vascular endothelial function. In vitro studies of shear stress and pinocytosis in bovine aortic cells. , 1984, The Journal of clinical investigation.

[117]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[118]  Lippincott Williams Wilkins,et al.  Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. , 1980, Circulation.

[119]  R. Ross,et al.  The pathogenesis of atherosclerosis (first of two parts). , 1976, The New England journal of medicine.

[120]  Thomas J. Bassler,et al.  Risk factors and coronary heart disease , 1976 .

[121]  M. Friedman.  Pathogenesis of coronary artery disease , 1969 .

[122]  W. Sterling Edwards,et al.  Blood Vessels , 1959 .